StreetInsider.com News Articles

Envoy Medical (NASDAQ:COCH) Signs Multi-Part Series With New to The Street

Tue, 02 Jun 2026 08:30:00 -0400

Envoy Medical to Launch National Media Awareness Campaign Highlighting a Global Hearing-Loss Market Affecting More Than 1.5 Billion People Worldwide

NEW YORK CITY, NY / ACCESS Newswire / June 2, 2026 / Envoy Medical, Inc. (NASDAQ:COCH), a hearing health innovator focused on fully implanted hearing technology, has signed a multi-part national media series with New to The Street. The campaign is designed to increase awareness among investors, and the broader marketplace about the company's groundbreaking approach to hearing.

The comprehensive program will feature executive interviews filmed from New York, national television broadcasts as

Envoy Medical (NASDAQ:COCH) Signs Multi-Part Series With New to The Street

Tue, 02 Jun 2026 08:30:00 -0400

Envoy Medical to Launch National Media Awareness Campaign Highlighting a Global Hearing-Loss Market Affecting More Than 1.5 Billion People Worldwide

The comprehensive program will feature executive interviews filmed from New York, national television broadcasts as

Form 8-K Envoy Medical, Inc. For: May 19

Fri, 22 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260522/26541549.html

Form 8-K Envoy Medical, Inc. For: May 19

Fri, 22 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260522/26541549.html

Envoy Medical Announces New Patents Expanding Intellectual Property Portfolio in Fully Implanted Hearing Technology

Wed, 20 May 2026 08:30:00 -0400

Australian and European Patent Offices Grant the Company Four Patents Relating to Key Innovations in Implantable System Design, Signal Analysis, and Battery Recharge Safety

White Bear Lake, Minnesota--(Newsfile Corp. - May 20, 2026) - Envoy Medical® Inc. (NASDAQ: COCH), a hearing health company pioneering fully implanted hearing solutions, today announced the issuance of multiple patents across Australia and Europe, as well as the upcoming grant of an additional European patent, further expanding the Company's intellectual property portfolio and reinforcing its position in the cochlear implant industry.

"As we continue advancing fully implanted hearing technology, protecting the innovation behind these systems

Envoy Medical Announces New Patents Expanding Intellectual Property Portfolio in Fully Implanted Hearing Technology

Wed, 20 May 2026 08:30:00 -0400

Australian and European Patent Offices Grant the Company Four Patents Relating to Key Innovations in Implantable System Design, Signal Analysis, and Battery Recharge Safety

"As we continue advancing fully implanted hearing technology, protecting the innovation behind these systems

Form 8-K Envoy Medical, Inc. For: May 12

Mon, 18 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260518/26513729.html

Form 8-K Envoy Medical, Inc. For: May 12

Mon, 18 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260518/26513729.html

Form SCHEDULE 13G Envoy Medical, Inc. Filed by: Nantahala Capital Management, LLC

Fri, 15 May 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260515/26507147.html

Form SCHEDULE 13G Envoy Medical, Inc. Filed by: Nantahala Capital Management, LLC

Fri, 15 May 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260515/26507147.html

Form SCHEDULE 13G Envoy Medical, Inc. Filed by: Bleichroeder LP

Thu, 14 May 2026 18:02:00 -0400

si-local-file:///var/storage/secattach/20260514/26497065.html

Form SCHEDULE 13G Envoy Medical, Inc. Filed by: Bleichroeder LP

Thu, 14 May 2026 18:02:00 -0400

si-local-file:///var/storage/secattach/20260514/26497065.html

Form SCHEDULE 13G/A Envoy Medical, Inc. Filed by: Ayrton Capital LLC

Mon, 11 May 2026 18:02:00 -0400

si-local-file:///var/storage/secattach/20260511/26470922.html

Form SCHEDULE 13G/A Envoy Medical, Inc. Filed by: Ayrton Capital LLC

Mon, 11 May 2026 18:02:00 -0400

si-local-file:///var/storage/secattach/20260511/26470922.html

Form 10-Q Envoy Medical, Inc. For: Mar 31

Mon, 11 May 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260511/26465750.html

Form 10-Q Envoy Medical, Inc. For: Mar 31

Mon, 11 May 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260511/26465750.html

Envoy Medical completes enrollment for fully implanted cochlear trial

Mon, 11 May 2026 08:02:57 -0400

Envoy Medical Inc. (NASDAQ: COCH) completed enrollment of 56 patients in its pivotal clinical trial for the Acclaim cochlear implant, marking what the company calls the first fully enrolled U.S. pivotal trial for a fully implanted cochlear device seeking FDA approval. The final patient was implanted on March 11, 2026.

The company also closed a public offering that raised $30 million in gross proceeds, with potential for up to $48 million more through milestone-linked warrants. The financing was led by Nantahala Capital and included Broadfin Holdings and existing shareholders.

Interim six-month data from the first 10 patients showed mean CNC word recognition

Form 8-K Envoy Medical, Inc. For: May 11

Mon, 11 May 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260511/26465412.html

Form 8-K Envoy Medical, Inc. For: May 11

Mon, 11 May 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260511/26465412.html

Envoy Medical Reports Landmark Accomplishments, Advancing Toward FDA Approval of First-of-Its-Kind Fully Implanted Cochlear Implant

Mon, 11 May 2026 08:00:00 -0400

Company Completes Historic Trial Enrollment, Secures Transformational Financing, and Sees Promising Early Clinical Data Presented at Industry Conferences

White Bear Lake, Minnesota--(Newsfile Corp. - May 11, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today reported first quarter 2026 results and landmark achievements that advance the Company another step closer toward commercialization of its investigational Acclaim® cochlear implant.

"The first quarter of 2026 marked a transformative period for Envoy Medical, highlighted by the completion of enrollment in our pivotal clinical trial and the successful execution of a significant financing,"

Envoy Medical Reports Landmark Accomplishments, Advancing Toward FDA Approval of First-of-Its-Kind Fully Implanted Cochlear Implant

Mon, 11 May 2026 08:00:00 -0400

Company Completes Historic Trial Enrollment, Secures Transformational Financing, and Sees Promising Early Clinical Data Presented at Industry Conferences

Envoy Medical shares six-month clinical data from cochlear implant study

Tue, 28 Apr 2026 08:35:14 -0400

Envoy Medical Inc. (NASDAQ: COCH) reported initial clinical data from the first 10 patients in its pivotal study of the investigational Acclaim cochlear implant. The data covers six-month follow-up visits for patients using the fully implanted hearing device.

According to presentations at medical conferences, no serious adverse events were reported in the study protocol. Reported adverse events were classified as mild or moderate and resolved with routine care or programming adjustments.

Speech recognition scores improved from a mean of 15.2% before implantation to 39.2% at six months, representing a 24 percentage point increase. Patients reported wearing the device 24 hours daily, compared

Envoy Medical Highlights First Clinical Data Presentations from Pivotal Clinical Study of Fully Implanted Acclaim(R) Cochlear Implant

Tue, 28 Apr 2026 08:30:00 -0400

Positive Initial 6-Month Data from First 10 Patients and Improvements in Speech Understanding and Quality of Life Scores Presented; Additional Presentations Scheduled in Early May

Details to be Discussed During Fireside Chat on April 29, 2026 at 4:30 pm ET

White Bear Lake, Minnesota--(Newsfile Corp. - April 28, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the first podium presentations of clinical data from the first stage of its pivotal clinical study of the investigational Acclaim^® cochlear implant, a first-of-its-kind, fully implanted

Envoy Medical Highlights First Clinical Data Presentations from Pivotal Clinical Study of Fully Implanted Acclaim(R) Cochlear Implant

Tue, 28 Apr 2026 08:30:00 -0400

Positive Initial 6-Month Data from First 10 Patients and Improvements in Speech Understanding and Quality of Life Scores Presented; Additional Presentations Scheduled in Early May

Details to be Discussed During Fireside Chat on April 29, 2026 at 4:30 pm ET

Envoy Medical Reaches Critical Milestone in Pivotal Clinical Trial of Fully Implanted Acclaim(R) Cochlear Implant

Wed, 22 Apr 2026 08:00:00 -0400

All 56 Enrolled Subjects Have Been Through Their Activation Visit Firming Up Study Timeline

White Bear Lake, Minnesota--(Newsfile Corp. - April 22, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that all 56 patients implanted and enrolled in its pivotal clinical trial evaluating the fully implanted Acclaim® cochlear implant have been through their "Activation Visits," when a patient's device is initially turned on for the first time.

"The conclusion of our trial studying the first-of-its-kind fully implanted Acclaim® cochlear implant is now within sight," said